Table 1.
Schedule of postimplementation evaluations.
Study day | Baseline assessment (day 1) | Final assessment (month 6) | ||
|
EHRa | Pathway Platform | Pathway Platform | EHR |
Demographic characteristics | ✓ | —b | — | — |
Number of PHQ-9c scores documented | ✓ | — | ✓ | ✓ |
Treatment adjustments | ✓ | — | ✓ | ✓ |
Referral to behavioral health | ✓ | — | — | ✓ |
PHQ-9 scores | ✓ | — | ✓ | — |
EDd visits | ✓ | — | — | ✓ |
ED visits due to mental illness | ✓ | — | — | ✓ |
Hospital admissions | ✓ | — | — | ✓ |
Follow-up after ED and hospital visits | ✓ | — | — | ✓ |
Hospital admissions due to mental illness | ✓ | — | — | ✓ |
Outpatient visits, including phone calls | ✓ | — | — | ✓ |
Outpatient visits, including phone calls due to mental illness | ✓ | — | — | ✓ |
Remission and response (using PHQ-9 data) | ✓ | — | ✓ | — |
PAM-13e | — | ✓ | ✓ | — |
CollaboRATE | — | ✓ | ✓ | — |
WSASf | — | ✓ | ✓ | — |
PHQ-9 | — | ✓ | ✓ | — |
WHO-5g | — | ✓ | ✓ | — |
PDQ-D-5h | — | ✓ | ✓ | — |
DSSTi | — | ✓ | ✓ | — |
Medication adherence | — | ✓ | ✓ | — |
Side effects | — | ✓ | ✓ | — |
PSD-6j (only if reporting side effects of sleep problems) | — | ✓ | ✓ | — |
ASEXk (only if reporting side effects of sexual problems) | — | ✓ | ✓ | — |
Goal setting | — | ✓ | — | — |
Goal attainment | — | — | ✓ | — |
App analytics | — | ✓ | ✓ | — |
Report analytics | — | ✓ | ✓ | — |
Educational material analytics | — | ✓ | ✓ | — |
AEsl or SAEsm,n | ✓ | ✓ | ✓ | ✓ |
aEHR: electronic health record.
b—: Not available.
cPHQ-9: 9-item Patient Health Questionnaire.
dED: emergency department.
ePAM-13: 13-item Patient Activation Measure.
fWSAS: Work and Social Adjustment Scale.
gWHO-5: 5-item World Health Organization Well-being Index.
hPDQ-D-5: 5-item Perceived Deficits Questionnaire–Depression.
iDSST: Digit Symbol Substitution Test.
jPSD-6: Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 6a.
kASEX: Arizona Sexual Experience Scale.
lAE: adverse event.
mSAE: serious adverse event.
nDuring the conduct of the study, adverse events or serious adverse events will be reported. As such, reports will be spontaneously notified, and causality of any AEs will be assumed unless there is evidence to the contrary.